Naloxone Drug Combination Buprenorphine

A pharmaceutical preparation that combines buprenorphine, an OPIOID ANALGESICS with naloxone, a NARCOTIC ANTAGONISTS to reduce the potential for NARCOTIC DEPENDENCE in the treatment of pain. It may also be used for OPIOID SUBSTITUTION THERAPY.

Also Known As:

Buprenorphine, Naloxone Drug Combination; Buprenorphine Naloxone; Buprenorphine Naloxone Drug Combination; Buprenorphine-Naloxone; Buprenorphine-Naloxone Combination; Buprenorphine-Naloxone Drug Combination; Suboxone; Buprenorphine Naloxone Combination; Combination, Buprenorphine-Naloxone; Combination, Buprenorphine-Naloxone Drug; Drug Combination, Buprenorphine-Naloxone; Naloxone, Buprenorphine

Networked: 539 relevant articles (78 outcomes, 112 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Fiellin, David A: 22 articles (12/2020 - 09/2004)
2.	Ling, Walter: 21 articles (06/2022 - 01/2004)
3.	Rotrosen, John: 17 articles (06/2022 - 01/2012)
4.	Nunes, Edward V: 13 articles (01/2022 - 11/2016)
5.	Weiss, Roger D: 12 articles (06/2020 - 03/2010)
6.	Griffin, Margaret L: 11 articles (06/2020 - 03/2010)
7.	Saxon, Andrew J: 10 articles (06/2022 - 01/2005)
8.	Schottenfeld, Richard S: 10 articles (01/2021 - 07/2006)
9.	Lee, Joshua D: 9 articles (01/2022 - 01/2012)
10.	Pavlicova, Martina: 8 articles (01/2022 - 09/2020)

Related Diseases

1.	Opioid-Related Disorders (Opiate Addiction) 01/01/2019 - "Screening for opioid use disorder in the ED and initiating buprenorphine/naloxone treatment with rapid referral to an outpatient community-based addictions clinic led to a 6-month treatment retention rate of 37% and a significant reduction in ED visits at 3 and 6 months. " 07/27/2006 - "Among patients receiving buprenorphine-naloxone in primary care for opioid dependence, the efficacy of brief weekly counseling and once-weekly medication dispensing did not differ significantly from that of extended weekly counseling and thrice-weekly dispensing. " 01/01/2023 - "Background: Although buprenorphine/naloxone has been demonstrated to be an effective treatment for patients with opioid use disorder (OUD), treatment retention has been a challenge. " 01/01/2023 - "Buprenorphine/naloxone has been shown to be effective for treating opioid use disorder (OUD). " 05/01/2022 - "Buprenorphine/naloxone is an effective medication for the treatment of opioid use disorder. "
2.	Substance Withdrawal Syndrome (Withdrawal Symptoms) 06/01/2023 - "The patient was successfully treated with buprenorphine/naloxone, which helped alleviate his withdrawal symptoms and allowed him to abstain from kratom. " 12/01/2019 - "Study outcomes were based on presence of withdrawal symptoms, instances of unauthorized substances in urine drug tests (UDTs), and sublingual buprenorphine/naloxone (SBN) dose with standard-of-care (SOC) dosing versus pharmacogenomics (PGx)-based dosing. " 11/01/2018 - "Her kratom-related withdrawal symptoms responded to a trial of buprenorphine-naloxone. " 01/01/2010 - "The average buprenorphine/naloxone dose in period 1 was 7.3 mg/day and 12.7 mg/day in period 2. Most patients did not experience any withdrawal symptoms in either period 1 or period 2. Fewer than 20% of patients experienced any cravings over the 120-day study period. " 07/01/2022 - "A relatively high dose of 16 mg/4 mg buprenorphine/naloxone successfully arrested withdrawal symptoms. "
3.	Pain (Aches) 01/01/2021 - "After initiating buprenorphine-naloxone, the patient reported rapid improvement in depressive symptoms, pain, and suicidal ideation. " 04/01/2022 - "Little is known about changes in pain during buprenorphine/naloxone (BUP/NX) maintenance and whether outcomes vary by pain levels. " 03/02/2021 - "Data gathered include psychiatric diagnoses, prescribed medications, pain score, buprenorphine/naloxone dosing, time in clinic, and reason for dismissal. " 03/01/2020 - "In this case series, the authors explore the frequency of buprenorphine-naloxone use and its outcomes in patients in a Compre-hensive Care Center (CCC) Pain Registry. " 01/01/2020 - "Pain was preceded by self-injection of dissolved buprenorphine/naloxone sublingual film onto the affected arm. "
4.	Chronic Pain 01/01/2022 - "Buprenorphine/naloxone has unique pharmacological properties that are beneficial in chronic pain treatment. " 01/01/2023 - "In this qualitative pilot study, 21 patients who were hospitalized for rotation to buprenorphine/naloxone as agonist treatment for chronic pain and OUD were offered MBCT. " 03/02/2021 - "Sublingual Buprenorphine/Naloxone and Multi-Modal Management for High-Risk Chronic Pain Patients." 01/15/2020 - "Rapid Induction of Buprenorphine/Naloxone for Chronic Pain Using a Microdosing Regimen: A Case Report." 01/01/2020 - "Male sex, less OAT experience, younger age, mental health conditions and chronic pain were associated with higher odds of buprenorphine/naloxone prescription. "
5.	Substance-Related Disorders (Drug Abuse) 07/01/2015 - "This is a secondary data analysis of the National Drug Abuse Treatment Clinical Trials Network 0003, a randomized clinical trial that compared buprenorphine/naloxone tapering strategies. " 04/15/2015 - "Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058." 07/01/2021 - "Younger patients and those with co-occurring substance use remain at higher risk of discontinuing buprenorphine/naloxone treatment for OUD in this population of ANAI people. " 07/01/2021 - "Younger age (hazard ratio 1.69, 95% confidence intervals 1.17-2.45) and co-occurring substance use (hazard ratio 2.95, 95% confidence intervals 1.99-4.38) were associated with increased rate of buprenorphine/naloxone treatment discontinuation. " 01/01/2021 - "A PPCPM for management of patients on MOUD with buprenorphine/naloxone was piloted in an outpatient substance use disorder clinic. "

Related Drugs and Biologics

1.	Buprenorphine (Subutex)
2.	Opioid Analgesics (Opioids)
3.	Methadone (Dolophine)
4.	Narcotic Antagonists (Opioid Antagonists)
5.	Naloxone Drug Combination Buprenorphine
6.	Naltrexone (ReVia)
7.	Tablets
8.	Naloxone (Narcan)
9.	trans-crotonin (CTN)
10.	Heroin (Diamorphine)

Related Therapies and Procedures

1.	Therapeutics
2.	Opiate Substitution Treatment
3.	Drug Substitution
4.	Glycemic Control
5.	Drug Therapy (Chemotherapy)